The biopharmaceutical industry contemplates product innovation within the changing landscape of healthcare.
Michael N. Abrams
Advertisement
Articles by Michael N. Abrams
A look back at the history of orphan drugs in the industry.
Rather than seeking a single indication for one large group, the orphan-drug approach segments the market for a drug more minutely.
Advertisement
Latest Updated Articles
The Affordable Care Act's Impact on Innovation in BiopharmaFebruary 1st 2014
- The Growing Orphan-Drug Paradigm
April 1st 2012
A 25-Year Retrospective on Orphan DrugsAugust 1st 2012
Advertisement
Advertisement
Trending on BioPharm International
1
AstraZeneca Acquires Omniose, Adding Bioconjugate Vaccine Platform
2
Amgen’s Dazodalibep Reduces Systemic Disease Activity in Phase 3 Sjögren’s Trial
3
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
4
The BioPharm Brief: FDA Designations for a Bispecific CAR-T, a BLA for Friedreich’s Ataxia, and Phase 2b MASH Data for Efinopegdutide
5